Huamin Zeng

Huamin Zeng

Auto-generated profile, based on publicly available information

Huamin Zeng

Cancer Prevention and Treatment Institute of Chengdu, Department of Pathology, Chengdu Fifth People’s Hospital (The Second Clinical Medical College, Affiliated Fifth People’s Hospital of Chengdu University of Traditional Chinese Medicine), Chengdu, Sichuan, 61137, People’s Republic of China

Research Focus & Metrics

Academic Career Length

3Years (2024-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 July 2024 in International Journal of Nanomedicine
Verified
Journal Article
Open access
PDF file
HZHuamin Zeng
Huamin Zeng
YZYiran Zhang
Yiran Zhang
NLNingyi Liu
Ningyi Liu
QWQingqing Wei
Qingqing Wei
FYFan Yang
Fan Yang
JLJIE LI
JIE LI
Introduction of exogenous genes into target cells to overcome various tumor diseases caused by genetic defects or abnormalities and gene therapy, a new treatment method, provides a promising strategy for tumor treatment. Over the past decade, gene therapy has made exciting progress; however, it still faces the challenge of low nucleic acid delivery and release efficiencies. The emergence of nonviral vectors, primarily nanodelivery and release systems (NDRS), has resulted in a historic breakthrough in the application of gene therapy. NDRS, especially stimulus-responsive NDRS that can respond in a timely manner to changes in the internal and external microenvironment (eg, low pH, high concentration of glutathione/reactive oxygen species, overexpressed enzymes, temperature, light, ultrasound, and magnetic field), has shown excellent loading and release advantages in the precision and efficiency of tumor gene therapy and has been widely applied. The only disadvantage is that poor transfection efficiency limits the in-depth application of gene therapy in clinical practice, owing to the presence of biological barriers in the body. Therefore, this review first introduces the development history of gene therapy, the current obstacles faced by gene delivery, strategies to overcome these obstacles, and conventional vectors, and then focuses on the latest research progress in various stimulus-responsive NDRS for improving gene delivery efficiency. Finally, the future challenges and prospects that stimulus-responsive NDRS may face in clinical application and transformation are discussed to provide references for enhancing in-depth research on tumor gene therapy.

1 October 2026 in International Journal of Nanomedicine
Verified
Journal Article
Open access
PDF file
JLJIE LI
JIE LI
WZWenbo Zhao
Wenbo Zhao
LXLiangliang Xue
Liangliang Xue
HLHanjing Liu
Hanjing Liu
YQYifan Qing
Yifan Qing
SCShilin Chen
Shilin Chen
Objective: Acute lung injury (ALI) features uncontrolled pulmonary inflammation and excessive reactive oxygen species (ROS), lacking effective targeted therapies. Hesperetin (HST) has anti-inflammatory and antioxidant effects, but poor solubility and weak lesion targeting limit its application. Herein, based on the characteristics of ALI lesion stromal cell-derived factor-1α (SDF-1α) and ROS overexpression, the authors constructed ROS-sensitive oxy-hydroxypropyl-β-cyclodextrin (Oxi-Hp-β-CD) and CXCR4-modified biomimetic nanoparticles (CXCR4-HST@BNPs) to achieve targeted (CXCR4/SDF-1α axis) and ROS-triggered HST delivery for the treatment of ALI. Methods: MLE-12 cells with overexpressed CXCR4 were constructed by lentiviral transduction and the cell membranes were extracted for encapsulating nanoparticles loaded with HST. Physicochemical properties, drug release profile, cellular uptake and in vivo distribution were characterized, and therapeutic efficacy and mechanisms were assessed using LPS-induced cellular and murine ALI models. Results: Prepared CXCR4-HST@BNPs possessed uniform particle size, high encapsulation efficiency and obvious ROS-dependent drug release. Benefiting from CXCR4/SDF-1α-mediated active targeting, the nanoparticles selectively accumulated in inflamed lung tissue with favorable acute biocompatibility. In vitro and in vivo experiments confirmed that CXCR4-HST@BNPs significantly alleviated pulmonary edema, suppressed pro-inflammatory cytokine overexpression and alleviated inflammatory injury. Mechanistically, the formulation eliminated excessive intracellular ROS, restored mitochondrial membrane potential and raised cellular ATP levels. Conclusion: In conclusion, CXCR4-HST@BNPs effectively ameliorate ALI via anti-oxidation and mitochondrial protection, representing a prospective ALI-targeted nanotherapeutic candidate.